- The Series B will fund Phase 1 trials for two RNAi therapies: ATL-201 for KCNT1-related epilepsy and ATL-101 for Huntington’s disease.
- The financing also includes the appointment of three new board members from EQT Life Sciences, Sanofi Ventures, and RiverVest Venture Partners.
Atalanta Therapeutics has successfully closed a $97 million Series B financing round to support the advancement of its investigational RNA interference (RNAi) therapies for KCNT1-related epilepsy and Huntington’s disease. The financing, co-led by EQT Life Sciences and Sanofi Ventures, brings the total capital raised by the company to $262 million.
Atalanta’s President and CEO, Alicia Secor, stated, “This financing validates the truly transformative potential of Atalanta’s best-in-class di-siRNA platform for delivering oligonucleotide therapies to the central nervous system.” She added that the funding would enable the company to progress its programs towards Investigational New Drug (IND) submissions by next year.
ATL-201, designed for KCNT1-related epilepsy, aims to reduce KCNT1 levels and normalize neuronal excitability, with promising preclinical results showing a significant reduction in seizures. Similarly, ATL-101 targets Huntington’s disease, with preclinical studies demonstrating a strong reduction in HTT gene expression and robust durability.